AlphaFold solved the reading problem. Now, new diffusion models are solving the writing problem. We are entering the era of "De Novo" protein design.

Instead of searching nature for a drug that might work, AI can now hallucinate a protein structure perfectly shaped to bind to a specific disease receptor. Early trials suggest this approach could increase the success rate of pre-clinical candidates by orders of magnitude.